Houston Ozempic & Wegovy Muscle Loss Lawyers — ENDO 2026 Study Confirms GLP-1 Users Lose Lean Mass and Cut Daily Activity, Attorney911 Brings 27+ Years of Federal-Court Trial Experience, We Pursue Novo Nordisk and Eli Lilly Under Texas Failure-to-Warn Law, Preserve Your Fitbit and Apple Health Data Before the 365-Day Overwrite, Two-Year Deadline Under Tex. Civ. Prac. & Rem. Code §16.003, Fragility Fracture Cases Reach $1M-$5M+ — Free Consultation, No Fee Unless We Win, Hablamos Español, 1-888-ATTY-911
You Lost the Weight. You Did Not Expect to Lose the Strength. You stepped on the scale and the number looked right. Maybe for the first time in years. The mirror told you what you wanted to hear. Friends told you that you looked great. The medication was working. But when you tried to stand up from a chair, your legs did not push back the way they used to. When you carried the grocery bags from the car, your arms shook. When you climbed the stairs, you had to stop at the top — breathing hard, legs trembling, the way your grandmother's legs used to tremble. The weight was gone. The strength was gone with it. When you mentioned the weakness to your doctor, you were told you looked fine, or to eat more protein, or that the fatigue would pass. It may not pass. A study presented at ENDO 2026 — the Endocrine Society's annual meeting in Chicago — confirms what you have been feeling in your body. Researchers following 753 adults who started a GLP-1 medication (semaglutide, liraglutide, dulaglutide, or tirzepatide) found that their average daily steps fell from 5,047 to 4,487. Their moderate-to-vigorous activity fell from…